Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Express Scripts
Harvard Business School

Last Updated: October 23, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for NOVA-22007

See Plans and Pricing

« Back to Dashboard

Drug Development Status for NOVA-22007: Patents, clinical trial progress, indications

NOVA-22007 is an investigational drug.

There have been 24 clinical trials for NOVA-22007. The most recent clinical trial was a Phase 3 trial, which was initiated on October 1st 2012.

The most common disease conditions in clinical trials are Diabetes Mellitus, Insulin Resistance, and Disease. The leading clinical trial sponsors are Canadian Institutes of Health Research (CIHR), Canadian Network for Observational Drug Effect Studies, CNODES, and Drug Safety and Effectiveness Network, Canada.

There are six hundred and seventy-six US patents protecting this investigational drug and sixteen international patents.

Recent Clinical Trials for NOVA-22007
Trial of Maintenance With Niraparib- Uterine Serous CarcinomaTesaro, Inc.Phase 2
Trial of Maintenance With Niraparib- Uterine Serous CarcinomaNorthwell HealthPhase 2
Lisdexamfetamine for Adults With Bulimia NervosaNova Scotia Health AuthorityPhase 2

See all NOVA-22007 clinical trials

Clinical Trial Summary for NOVA-22007

Top disease conditions for NOVA-22007
Top clinical trial sponsors for NOVA-22007

See all NOVA-22007 clinical trials

US Patents for NOVA-22007

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
NOVA-22007   Start Trial Antidiabetic tricyclic compounds Merck Sharp & Dohme (Rahway, NJ)   Start Trial
NOVA-22007   Start Trial Heterocyclic compounds that inhibit the kinase activity of Mnk useful for treating various cancers eFFECTOR Therapeutics, Inc. (San Diego, CA)   Start Trial
NOVA-22007   Start Trial Small molecules for the modulation of MCL-1 and methods of modulating cell death, cell division, cell differentiation and methods of treating disorders Dana-Farber Cancer Institute, Inc. (Boston, MA)   Start Trial
NOVA-22007   Start Trial Phosphonate compounds for treatment of medical disorders Achillion Pharmaceuticals, Inc. (New Haven, CT)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for NOVA-22007

Drugname Country Document Number Estimated Expiration Related US Patent
NOVA-22007 Australia 2015263620 2034-05-22   Start Trial
NOVA-22007 Canada 2947781 2034-05-22   Start Trial
NOVA-22007 China 106458913 2034-05-22   Start Trial
NOVA-22007 European Patent Office 3145915 2034-05-22   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.